www.standoutstocks.com: Stocks That Stand Out For Oct. 29th, 2009 Are HRRN, LLFH, GETA, AMLM, IMGG

Stocks That Standout For Oct. 29th, 2009 are HE-5 Resources, Corp. (PINK SHEET: HRRN), L & L International Holdings, Inc. (OTC Bulletin Board: LLFH), Genta Incorporated (OTCBB: GETA), American Lithium Minerals Inc. (OTCBB: AMLM), Imaging3, Inc. (OTCBB: IMGG)

Visit Us On Twitter and Facebook: http://twitter.com/StandoutStocks http://www.facebook.com/people/Standout-Stocks/547603354

Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at HYPERLINK "http://www.Standoutstocks.com/" www.Standoutstocks.com __________________________________________________ HE-5 Resources Corp, Announces Management in Negotiation with Merchant Bankers For Major Financial Partnership and License Sale in Eastern Europe

NEW YORK CITY, NEW YORK, Oct 29, 2009 -- HE-5 Resources, Corp. (PINK SHEET: HRRN), Today announced Management in negotiation with Merchant Bankers for major financial partnership and license sale in Eastern Europe.

Following the announcement of management reviewing potential options for stock buyback, the Company has accelerated "Trading Barter Bank" developments with Eastern Europe Contacts who had been in discussions for purchasing a TBB License for a while.

Our new business associates are specialized in merchant banking and Equity Capital Investments. The license agreement would exceptionally comprise 3 Countries and first option for 3 others. The parties have proposed their involvement in the program and management has received their proposals yesterday and have been exchanging and discussing since then.

Management will continue negotiations and preparing for meetings within the next couple of days. The main objective is to structure a license deal including a stock participation program combined with other management actions regarding the current stock value. The merchant bankers have a large network of broker dealer firms who are very active in the young Eastern Europe Market, and who are favorable to the new internet financial products market.

Mr. Rick DesOrmeaux CFO expressed the followings: "We had planned to be in the Eastern Europe market in spring 2010, but our associates' interest has leaded us to take the opportunity. Secondly we feel that through utilizing the strength of the network, combined with corporate actions will we rapidly gain from this association and provide our shareholders better values. I forecast the potential of this agreement to provide our company a very powerful financial position." Management will keep the shareholders informed and we invite you to visit our forum at www.unitedbusinesstraders.com and suggest you fill the online registration form to receive member packages.

You can visit our corporate web site at: www.tradingbartercorp.com Forward-Looking Statements Please be advised that statements made herein, other than historical data, constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include, among others, potential volatility in the company's stock price, increased competition, customer acceptance of new products and services offered by the company, and uncertainty of future revenue and profitability and fluctuations in its quarterly operating results. Please also be advised that the company's stock is not currently registered with the Securities and Exchange Commission.

L&L International Announces Definitive Agreement to Acquire Hon Shen Coking Operations

--Expects to add approximately $18 million in additional revenue to L&L in one year

SEATTLE, Oct 29, 2009 -- L & L International Holdings, Inc. (OTC Bulletin Board: LLFH) ("L&L"), a U.S.-based company operating coal businesses in China, announced today that it has executed an agreement with Hon Shen Coal Company Ltd. ("Hon Shen"), located in Yunnan Province, China, to acquire a 93% interest in Hon Shen coking facilities and an additional 28% interest in the Hon Shen coal-washing facilities for a purchase price of $8.18 million consisting of a combination of cash and shares of the Company's common stock. Through the agreement, L&L 1) increases its controlling interest in Hon Shen coal washing facilities from 65% to 93%; and 2) acquires a 93% controlling interest in Hon Shen's coking facilities. The acquisition was effective October 23, 2009; contingent upon government approval.

Hon Shen's coal washing facilities share a combined annual coal washing capacity of 300,000 tons: a 210,000-ton coal washing plant and an existing 90,000-ton plant.

Hon Shen's coking facilities have a combined annual production capacity of 150,000 tons, and will add approximately $18 million in additional revenue to L&L in one year, using $150 per ton of coking coal as a basis (based on 120,000 tons).

Dickson Lee, Chairman and CEO of L&L, stated: "These latest acquisitions are a continuance of our planned expansions for fiscal year 2010. We are excited to expand our relationship with Hon Shen as we work to improve production, operational efficiency, and environmental and safety standards at the Hon Shen facilities. The planned acquisitions will further our goal of becoming a vertically integrated energy company serving China's high demand for energy and coal." About L&L International Holdings Founded in 1995 and headquartered in Seattle, Washington, L&L serves the vast energy market in China. For more information, please visit Company's website at http://www.lnlinternational.com.

Forward-Looking Statements

The statements contained in this document that are not statements of historical fact, including but not limited to, statements using terms such as "anticipate," "estimate," "expect", "plan," "could," and other expressions, including statements related to market trends and Company's future performance, are all "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve a number of risks and uncertainties. The actual results of the future events described in the forward-looking statements in this document could differ materially from those stated due to numerous factors identified in SEC filings made by the Company. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Genta Announces Top-Line Results of AGENDA Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma

BERKELEY HEIGHTS, N.J., Oct 29, 2009 -- Genta Incorporated (OTCBB: GETA) today announced top-line results from AGENDA, the Company's Phase 3 trial of Genasense(R) (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine administered with or without Genasense(R) in patients who have not previously received chemotherapy. As defined in a prior randomized trial, AGENDA uses a biomarker to define patients who might maximally benefit from treatment.

AGENDA did not show a statistically significant benefit for its co-primary endpoint of progression-free survival. Secondary endpoints of overall response rate and disease control rate (which includes complete and partial responses, plus stable disease greater-than or equal to 3 months duration) also did not show a statistically significant benefit. According to the prespecified analysis plan, the statistical significance of durable response -- a secondary endpoint that measures the proportion of patients who achieved a complete or partial response that lasts greater-than or equal to 6 months -- is too early to evaluate. The observed differences in progression-free survival, overall response, disease control and durable response all numerically favored the group that received Genasense(R).

Overall survival -- the other co-primary endpoint in AGENDA -- is too early to evaluate, as prospectively specified. An analysis for futility, which was defined as greater-than or equal to 50% conditional power to observe a statistically significant benefit of Genasense under the prospectively assumed hazard ratio of 0.69, has been conducted for the co-primary endpoint of overall survival. AGENDA has passed this futility analysis. The prospectively specified analyses for both overall survival and durable response will be conducted when the data are mature. The safety profile of Genasense in AGENDA was consistent with prior studies.

Quantitative details of the today's announced results will be presented at the international conference, "Molecular Targets and Cancer Therapeutics", that will be held November 15-19, 2009 in Boston, MA. The AGENDA results will be featured in an oral session on Monday November 15, 2009 at 5:00 PM ET. The "Targets Meeting" is jointly sponsored by the American Association for Cancer Research (AACR), the U.S. National Cancer Institute (NCI), and the European Organization for Research and Treatment of Cancer (EORTC) "At this time, we cannot predict whether more mature data will reveal a benefit in either overall survival or durable response," said Dr. Raymond P. Warrell., Jr., Genta's Chief Executive Officer. "However, the immediate failure to confirm a significant improvement in progression-free survival will preclude our submission of a regulatory application this year. Management and the Board are currently assessing the impact of these data on the Company's strategic direction. The Company plans to provide further updates in the near future. Genta is very grateful for the tireless dedication of our employees and for the contributions of the many physicians, patients, and families who have worked to advance Genasense for the treatment of melanoma." Conference Call Genta management will host a conference call and live audio webcast to discuss results of the AGENDA trial on Thursday October 29, 2009 at 8:00 AM ET.

Participants can access the live call by dialing (877) 634-8606 (U.S. and Canada) or (973) 200-3973 (International). The access code for the live call is Genta Incorporated. The call will also be webcast live at http://www.genta.com/investorrelation/events.html For investors unable to participate in the live call, a replay will be available approximately two hours after the completion of the call, and will be archived for 30 days. Access numbers for this replay are: (800) 642-1687 (U.S. and Canada) and (706) 645-9291 (International); conference ID number is: 38149996.

About AGENDA

AGENDA is a Phase 3, randomized, double-blind, placebo-controlled trial of dacarbazine administered with or without Genasense(R) in patients who have not previously received chemotherapy. AGENDA employs a biomarker to define those patients who derived maximum clinical benefit during the preceding study. These patients are characterized by low-normal levels of LDH (lactate dehydrogenase), a tumor-derived enzyme that is readily detected in blood.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genasense is being developed as an agent that may enhance the effectiveness of current anticancer therapy. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, which has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact. The words "potentially", "anticipate", "could", "calls for", and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements. Factors that could affect actual results include, without limitation, risks associated with: -- the Company's ability to obtain necessary regulatory approval for Genasense(R) from the U.S. Food and Drug Administration ("FDA"); -- the safety and efficacy of the Company's products or product candidates; -- the commencement and completion of clinical trials; -- the Company's assessment of its clinical trials; -- the Company's ability to develop, manufacture, license and sell its products or product candidates; -- the Company's ability to enter into and successfully execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, the Company's ability to obtain sufficient financing to maintain the Company's planned operations, or the Company's risk of bankruptcy; -- the adequacy of the Company's patents and proprietary rights; -- the impact of litigation that has been brought against the Company; and -- the other risks described under Certain Risks and Uncertainties Related to the Company's Business, as contained in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2008 and its most recent quarterly report on Form 10-Q.

American Lithium Minerals Joins the "AGORACOM 100" and Launches Online Investor Relations Program

HENDERSON, NV, Oct 29, 2009 -- American Lithium Minerals Inc. (OTCBB: AMLM) -- (the "Company") is pleased to announce it has retained the services of AGORACOM Investor Relations ("AGORACOM") (http://www.agoracom.com) to provide online investor relations services, a Web 2.0 social network for current shareholders and Tier-1 awareness through the world's biggest websites for the purpose of attracting new shareholders. ONLINE INVESTOR RELATIONS MAXIMIZES SPEED, TRANSPARENCY AND ACCESS TO COMPANY In response to overwhelming data representing the online research and communications habits of small-cap investors, American Lithium Minerals has turned the primary focus of its investor relations to the web via AGORACOM to facilitate faster, better and more accessible communications with both current and prospective shareholders around the world.

Effective October 29, 2009, a customized and monitored American Lithium Minerals IR HUB will be available on AGORACOM at (http://agoracom.com/ir/americanlithium). The IR HUB will allow American Lithium Minerals to communicate with all investors simultaneously, anytime and in near real-time through our electronic shareholder forum. This HUB will provide American Lithium Minerals management with the ability to extend communications beyond text via audio messages, video presentations, webcasts and podcasts. In addition to traditional e-mail, investors will also have the ability to receive all communications via RSS feed.

LAUNCH OF AMERICAN LITHIUM MINERALS SHAREHOLDER COMMUNITY

The American Lithium Minerals IR HUB propels the Company into the forefront of Web 2.0 investor relations by providing investors with two very important functions. First, a monitored discussion forum for the purposes of constructive and high-quality discussion amongst investors that is free of spam, profanity and misinformation. Second, a social network that provides investors with the ability to create extensive profiles that include photos, bios, video messages to fellow investors, a rating system and other important items to create a closer bond between our shareholders.

THE "AGORACOM 100"

On January 19th, AGORACOM launched a national TV, web and search engine marketing campaign to drive small-cap investors to the AGORACOM 100, an elite and exclusive group of great small-cap companies in which American Lithium Minerals will be included. This marketing campaign will target main stream media including regular spots on BNN, CNBC TV, Bloomberg TV, Globe & Mail's GlobeInvestor.com, Google, Yahoo!, MSN, AOL, Facebook, AGORACOM and other Tier 1 media properties.

TIER-1 EXPOSURE AND AWARENESS

As an exclusive provider of Small-Cap news and information to Tier 1 sites such as Globe Investor, Yahoo Finance Canada, AOL Finance Canada and every BlackBerry device on the planet, AGORACOM will provide significant financial media coverage of all newsworthy American Lithium Minerals press releases for the purposes of attracting new and prospective shareholders.

Judy Baker, President and CEO of American Lithium Minerals states, "I believe the time has now come to significantly increase our communications with both existing shareholders and the massive online small-cap community of investors that are searching for their next great investment. I strongly encourage our shareholders to begin taking advantage of our new online IR system, which demonstrates we are a fully accessible organization with a great story to tell." For all future American Lithium Minerals investor relations needs, investors are asked to visit our IR Hub at http://agoracom.com/ir/americanlithium where they can post questions and receive answers within the same day, or simply review questions and answers posted by other investors.

About AGORACOM

AGORACOM Investor Relations (http://www.AgoracomIR.com) is North America's largest online investor relations firm for small-cap companies. We have partnered with the world's biggest internet companies, including Yahoo, Globe Investor, AOL, Google and BlackBerry to market our clients to a massive audience of new small-cap investors. We have served over 300 companies since 1997.

AGORACOM (http://www.Agoracom.com) is North America's only small-cap community built to serve the needs of serious small-cap and micro-cap investors. No rumours, profanity, stock bashing or hyping. Our traffic ranking is above the top 0.5% of all websites around the world.

About American Lithium Minerals

American Lithium Minerals Inc. is an early stage lithium exploration company engaged in evaluating, developing and acquiring lithium projects, with a focus on the USA.

Forward-Looking Statements

This current report contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, the entry into of a definitive option agreement with GeoXplor in regards to the claims situated on the Montezuma Peak in Esmeralda County, Nevada, of our ability to make any required payments in regards to the claims and option agreement as they become due.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with mineral exploration and difficulties associated with obtaining financing on acceptable terms. We are not in control of lithium prices and these could vary to make development uneconomic. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Imaging3 to Host Conference Call Regarding FDA Approval Progress

BURBANK, CA, Oct 28, 2009 -- Imaging3(TM), Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, announced today that on Thursday, October 29, 2009 at 10:00am PDT (1:00pm EDT) the company's CEO, Mr. Dean Janes, will be hosting a conference call to provide an update on the company's progress with the FDA to date.

To join the conference call, please call 1-888-732-6202 and enter passcode 354791 followed by the pound sign (#). You will be connected to the conference call in a listen only mode, and then lines will be opened for questions following the presentation. A recording of the conference call will also be available on the company's website within 24 hours following the conference call.

About Imaging3

Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company's website at http://www.imaging3.com for more information.

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, technological obsolescence, competition from other medical instrument(s) and imaging companies, lack of capital, unexpected costs, failure or delay of FDA approval, absence of revenue, the impact on the national and local economies resulting from an economic recession or terrorist actions, and U.S. actions subsequently; unavailability of financing for the Company or its customers, product malfunction and potential product liability claims, and other factors detailed in reports filed by the Company.

About Standoutstocks

www.Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

www.Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at http://www.Standoutstocks.com and select the "join now" button.

Join us at http://www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: http://www.standoutstocks.com/disclaimer.aspx

CONTACT: Jason A. Hilton, Standout Stocks Tel: +1 585 729 8809 e-mail: Jason@Newmediaadvisorsllc.com e-mail: info@standoutstocks.com WWW: http://www.standoutstocks.com

CONTACT: Jason A Hilton, Standout Stocks Tel: +1 585 729 8809 e-mail: Jason@Newmediaadvisorsllc.com e-mail: info@standoutstocks.com WWW: http://www.standoutstocks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: acquisition, annual report, bank, banking, bankruptcy, bond, broker, business, california, canada, cancer, ceo, china, clinical, coal, communications, community, conference, corporate, dealer, disease, distributor, dna, drugs, email, e-mail, energy, equity, europe, exploration, fda, finance, forecasts, government, hosting, internet, investment, investment opinion, local, manufacturer, market, marketing, media, medical, micro cap, national cancer institute, nevada, new york, nitrate, north america, online, otc, partnership, physicians, plant, president, prices, products, research, revenue, sec, securities, small cap, standards, subscription, technology, traffic, trial, tv, video, web